Interactions between tumor microenvironment and resistance to transarterial and systemic treatments for HCC
Fibroblast growth factor receptor alterations and resistance mechanisms in the treatment of pediatric solid tumors
Acquired resistance to molecularly targeted therapies for cancer
PER2 expression and cellular localization play a critical role in tumor aggressiveness and drug resistance in an <i>in vitro</i> model of hepatocellular carcinoma
ZEB2 upregulation modulates the polarization of TAMs toward the immunosuppressive state in EGFR-TKI-resistant NSCLC
FGFR1 overexpression promotes resistance to PI3K inhibitor alpelisib in luminal breast cancer cells through receptor tyrosine kinase signaling-mediated activation of the estrogen receptor
Mechanisms of resistance to NAMPT inhibitors in cancer
Circular RNAs modulate cancer drug resistance: advances and challenges
Exosomal miR-92b-5p regulates N4BP1 to enhance PTEN mono-ubiquitination in doxorubicin-resistant AML
Research advances in natural sesquiterpene lactones: overcoming cancer drug resistance through modulation of key signaling pathways
Unraveling <i>BRAF</i> alterations: molecular insights to circumvent therapeutic resistance across cancer types
The epigenetic mechanisms involved in the treatment resistance of glioblastoma
Antibody-drug conjugates in breast cancer treatment: resistance mechanisms and the role of therapeutic sequencing
Sophisticated roles of tumor microenvironment in resistance to immune checkpoint blockade therapy in hepatocellular carcinoma
Overcoming drug resistance in castrate-resistant prostate cancer: current mechanisms and emerging therapeutic approaches
Exploring YAP1-related TIME in SCLC: implications for survival and treatment response to immuno-chemotherapy
Metabolic crossroads: unravelling immune cell dynamics in gastrointestinal cancer drug resistance
Histone deacetylases in the regulation of cell death and survival mechanisms in resistant BRAF-mutant cancers
Optimizing therapeutic approaches for HR+/HER2- advanced breast cancer: clinical perspectives on biomarkers and treatment strategies post-CDK4/6 inhibitor progression
Regulatory role of non-coding RNAs in 5-Fluorouracil resistance in gastrointestinal cancers
Integrative multi-omics analysis for identifying novel therapeutic targets and predicting immunotherapy efficacy in lung adenocarcinoma
Cancer-associated fibroblast-derived extracellular vesicles: regulators and therapeutic targets in the tumor microenvironment
Ferroptosis-related signaling pathways in cancer drug resistance
Strategies to combat cancer drug resistance: focus on copper metabolism and cuproptosis
The genetic architecture of bone metastases: unveiling the role of epigenetic and genetic modifications in drug resistance
Ivosidenib enhances cisplatin sensitivity in ovarian cancer by reducing cancer cell stemness
Tumor microenvironment-driven resistance to immunotherapy in non-small cell lung cancer: strategies for Cold-to-Hot tumor transformation
Unveiling MAGEA3: a novel predictive biomarker for bevacizumab resistance in colorectal cancer
Advances in the application of patient-derived xenograft models in acute leukemia resistance
Antibody-drug conjugates in breast cancer: current resistance mechanisms and future combination strategies
MicroRNA-mediated autophagy regulation in thyroid cancer drug resistance
Integrated multi-omics profiling of immune microenvironment and drug resistance signatures for precision prognosis in prostate cancer
Modeling methods of different tumor organoids and their application in tumor drug resistance research
The next frontier in antibody-drug conjugates: challenges and opportunities in cancer and autoimmune therapy